Disease: Acute COVID-19

Ismail

Greece Denmark Germany
|
2020-2022
  • Adults
  • General population
  • Elderly
  • Hospital wide
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Statins

Rinaldi

Italy
|
2022-2022
  • Adults
  • General population
  • Elderly
  • Fragile population
  • Immunocompromised host
  • Outpatient clinic
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Nirmatrelvir/Ritonavir
  • Remdesivir
  • Molnupiravir

Perrotta

Italy
|
2021-2022
  • Adults
  • General population
  • Elderly
  • Fragile population
  • Hospital wide
  • Emergency department
  • Infectious diseases unit
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Monoclonal antibodies
  • Sotrovimab
  • Tixagevimab/Cilgavimab
  • Casirivimab/Imdevimab
  • Bamlanivimab/ Etesevimab

Gentile

Italy
|
2023-2023
  • Adults
  • General population
  • Elderly
  • Fragile population
  • Hospital wide
  • Emergency department
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Nirmatrelvir/Ritonavir
  • Remdesivir
  • Monoclonal antibodies
  • Sotrovimab

Drysdale

United Kingdom
|
2022-2022
  • Adults
  • Elderly
  • Fragile population
  • Primary care
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Nirmatrelvir/Ritonavir
  • Monoclonal antibodies
  • Sotrovimab
  • Molnupiravir

Rotundo

Italy
|
2022-2023
  • Adults
  • Fragile population
  • Immunocompromised host
  • Outpatient clinic
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Nirmatrelvir/Ritonavir
  • Remdesivir
  • Monoclonal antibodies
  • Sotrovimab
  • Molnupiravir
  • Tixagevimab/Cilgavimab
  • Casirivimab/Imdevimab

Nguyen

France
|
2021-2022
  • Adults
  • Fragile population
  • Immunocompromised host
  • Hospital wide
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Monoclonal antibodies
  • Tixagevimab/Cilgavimab

PANTHER

United Kingdom
|
2026
  • Adults
  • General population
  • Infants (<1 year)
  • Infants (less than 1 year)
  • Hospital wide
  • Intensive care unit
  • SARS-CoV-2
  • Influenza virus
  • Influenza A(H5N1) virus
  • Acute COVID-19
  • Avian Influenza
  • Influenza
  • Pharmacological intervention
  • Immunomodulator
  • Baricitinib
  • Statins
  • Simvastatin

EU-PROACT

France Norway Spain Belgium Italy United Kingdom Ireland Austria The Netherlands Switzerland
|
2025
  • Adults
  • General population
  • Hospital wide
  • SARS-CoV-2
  • Influenza virus
  • Influenza A(H5N1) virus
  • Acute COVID-19
  • Avian Influenza
  • Influenza

ECRAID-PRIME

Belgium France Germany Ireland Poland Spain United Kingdom Georgia
|
2024
  • Adults
  • Community
  • Primary care
  • SARS-CoV-2
  • Influenza virus
  • Influenza A(H5N1) virus
  • Acute COVID-19
  • Avian Influenza
  • Influenza
  • Pharmacological intervention
  • Nitric Oxide Nasal Spray

ECRAID-REMAP-CAP

Belgium Croatia Czech Republic Estonia France Germany Hungary Ireland Italy The Netherlands Portugal Serbia Slovenia Spain Switzerland United Kingdom
|
2018
  • Adults
  • Hospital wide
  • Intensive care unit
  • SARS-CoV-2
  • Influenza virus
  • Influenza A(H5N1) virus
  • Acute COVID-19
  • Avian Influenza
  • Influenza
  • Pharmacological intervention
  • Immunomodulator
  • Corticosteroid
  • Baloxavir
  • Oseltamivir

EuCARE-HOSPITALISED

Sweden Italy Poland Portugal Germany Lithuania United Kingdom Kenya Brazil Mexico
|
2022
  • Adults
  • Hospital wide
  • Emergency department
  • SARS-CoV-2
  • Acute COVID-19
  • Blood sample
  • Nasopharyngeal swab
  • Urine sample